Journal of Advanced Biomedical Sciences
JABS
Tue, Oct 7, 2025
[Archive]
Autumn 2025 (In Press)
Back to the articles list |
Back to browse issues page
1- Student Research Committee, Fasa University of Medical Sciences, Fasa, Iran
2- Noncommunicable Diseases Research Center, Fasa University of Medical Sciences, Fasa, Iran
3- Noncommunicable Diseases Research Center, Fasa University of Medical Sciences, Fasa, Iran ,babakpezeshki@yahoo.com
2- Noncommunicable Diseases Research Center, Fasa University of Medical Sciences, Fasa, Iran
3- Noncommunicable Diseases Research Center, Fasa University of Medical Sciences, Fasa, Iran ,
Abstract: (13 Views)
Elevated low-density lipoprotein cholesterol (LDL-C) is a key modifiable risk factor for cardiovascular disease. While statins are the cornerstone of LDL-C-lowering therapy, their long-term use may result in dose-dependent adverse effects. Ezetimibe, a Niemann–Pick C1-Like 1 inhibitor, reduces intestinal cholesterol absorption and complements the reduction of hepatic cholesterol synthesis achieved through statin therapy. Evidence from major trials, including IMPROVE-IT, SHARP, RACING, and EWTOPIA 75, demonstrates that combination therapy achieves greater LDL-C reduction and provides modest improvements in clinical outcomes compared with statin monotherapy, while maintaining a favorable safety profile. The early initiation of combination therapy may permit the use of lower statin doses, thereby reducing adverse effects such as insulin resistance and hepatotoxicity. The co-administration of ezetimibe with statins, when implemented alongside guideline-recommended strategies, represents a rational and patient-centered approach for high-risk individuals. This strategy offers enhanced lipid control and improved safety outcomes relative to statin monotherapy.
Keywords: LDL, Ezetimibe, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Cardiovascular Diseases, Hyperlipidemias
Type of Study: Letter to the Editor |
Subject:
Pharmacology
Received: 2025/07/14 | Accepted: 2025/09/27
Received: 2025/07/14 | Accepted: 2025/09/27
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
This work is licensed under a Creative Commons — Attribution-NonCommercial 4.0 International (CC BY-NC 4.0)